Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2002
04/04/2002WO2002026741A1 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN
04/04/2002WO2002026740A1 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione and the use thereof for the treatment of pain
04/04/2002WO2002026739A1 1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain
04/04/2002WO2002026738A1 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN
04/04/2002WO2002026737A1 Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
04/04/2002WO2002026736A1 A thiazolidinedione derivative and its use as antidiabetic
04/04/2002WO2002026735A1 Sodium salts of 5-'4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
04/04/2002WO2002026734A1 PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR Xa
04/04/2002WO2002026733A2 sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES
04/04/2002WO2002026730A2 Fluorinated quinolones as antimitotic and antitumor agents
04/04/2002WO2002026729A2 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
04/04/2002WO2002026727A2 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai
04/04/2002WO2002026724A1 Cyclized benzamide neurokinin antagonists for use in therapy
04/04/2002WO2002026723A1 Compounds useful in the treatment of inflammatory diseases
04/04/2002WO2002026722A1 Morpholin-acetamide derivatives for the treatment of inflammatory diseases
04/04/2002WO2002026717A2 Hydroxy acid integrin antagonists
04/04/2002WO2002026716A2 Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections
04/04/2002WO2002026713A1 Antiparasitic compounds
04/04/2002WO2002026711A1 Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
04/04/2002WO2002026708A1 Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient
04/04/2002WO2002026704A1 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents
04/04/2002WO2002026696A1 Carbamic acid compounds comprising an amide linkage as hdac inhibitors
04/04/2002WO2002026694A1 O-substituted 6-methyl-tramadol derivatives
04/04/2002WO2002026325A2 Restoration of perturbed barrier function by application of antiandrogens
04/04/2002WO2002026324A2 Tocol-based compositions containing amiodarone
04/04/2002WO2002026281A1 Coated medical devices
04/04/2002WO2002026279A1 E-ptfe foil impregnated with an encapsulated bioactive substance
04/04/2002WO2002026277A2 Stabilized hydrogen peroxide solutions
04/04/2002WO2002026249A2 Methods for inhibition of viral infection
04/04/2002WO2002026245A2 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
04/04/2002WO2002026242A2 Inhibition of systemic infections in humans and vertebrates by dietary fibers
04/04/2002WO2002026240A2 Inhibition of antigen presentation with poorly catabolized polymers
04/04/2002WO2002026239A1 Analgesic and glucosamine compositions
04/04/2002WO2002026238A1 Phosphate derivative supplements
04/04/2002WO2002026236A1 Tumor cell killing by cell cycle checkpoint abrogation combined with inhibition of the 'classical' mitogen activated protein (map) kinase pathway
04/04/2002WO2002026235A1 Dispersible pharmaceutical cephalosporin compositions, preparation and use thereof
04/04/2002WO2002026234A1 Eye drops comprising acyclovir suspension
04/04/2002WO2002026232A1 Pharmaceutical composition for transmucosal delivery of a dihydroergotamine/metoclopramide combination
04/04/2002WO2002026231A1 Use of nitroxides for the treatment of vascular disorders in a diabetic mammal
04/04/2002WO2002026227A1 Lactone integrin antagonists
04/04/2002WO2002026226A1 Pharmaceutical composition of dihydroartemisinin for treating malaria
04/04/2002WO2002026225A1 Methods for in vivo reduction of free radical levels and compositions useful therefor
04/04/2002WO2002026224A2 Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
04/04/2002WO2002026223A2 Catecholamine pharmaceutical compositions and methods
04/04/2002WO2002026222A2 Method of achieving overnight laxation and control of bowel function
04/04/2002WO2002026219A2 Otic microbial combinations for treatment of animals with ruptured tympanic membrane
04/04/2002WO2002026218A2 Fatty acid analogues for the treatment of proliferative skin disorders
04/04/2002WO2002026217A2 Composition for the transdermal delivery of fentanyl
04/04/2002WO2002026216A1 Pharmaceutical oxan preparation
04/04/2002WO2002026215A2 Thermogelling biodegradable aqueous polymer solution
04/04/2002WO2002026214A1 Ion-strength independent sustained release pharmaceutical formulation
04/04/2002WO2002026211A1 Topical polymeric antimicrobial emulsion
04/04/2002WO2002026193A2 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
04/04/2002WO2002026104A2 A combination of appetite controlling agents which create a synergy and produce a satiating result
04/04/2002WO2002026020A2 Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics
04/04/2002WO2002014281A8 Pyridine derivatives as inhibitors of p38
04/04/2002WO2002010339A3 Gene expression profile for kshv infection and methods for treating same
04/04/2002WO2002008195A8 Pyrazolyl biphenyl carboxamides and the use thereof for controlling undesired microorganisms
04/04/2002WO2002006248A3 Cyclic oxyguanidine pyrazinones as protease inhibitors
04/04/2002WO2002004421A3 Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
04/04/2002WO2002004407A3 7-substituted tetracycline compounds
04/04/2002WO2002002084A8 Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
04/04/2002WO2002000662B1 Improvements in and relating to chromophores
04/04/2002WO2002000167A3 Modified forms of pharmacologically active agents and uses therefor
04/04/2002WO2002000042A3 Compositions and methods for body weight management
04/04/2002WO2001097815A3 Use of glucocorticosteroids for producing a medicament to treat oligotrichia
04/04/2002WO2001097795A3 Systems and methods for treating a mucosal surface
04/04/2002WO2001097771A3 Preparations that contain an extract of the plant pistia stratiotes
04/04/2002WO2001094347A8 Tetracyclic diketopiperazine compounds as pdev inhibitors
04/04/2002WO2001094301A3 Factor viia inhibitory (thio)urea derivatives, their preparation and their use
04/04/2002WO2001093844A3 Compositions comprising a serotonin transporter inhibitor and a 5-ht1d antagonist
04/04/2002WO2001091735A3 Use of aloe-emodin in the treatment of neuroectodermal tumors
04/04/2002WO2001091733A3 Combination of active substances containing montirelin and a compound having an opioid effect
04/04/2002WO2001090306A3 Compositions and methods for modulating tumor specific expression
04/04/2002WO2001090137A3 NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11β-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETHYL-17β-METHOXY-ESTRA-4,9-DIEN-3-ONE
04/04/2002WO2001090079A3 Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists
04/04/2002WO2001089577A3 Conjugates of aminodrugs comprising an oxime bond
04/04/2002WO2001089451A3 Protease inhibitors
04/04/2002WO2001089449A3 Phospholipase d effectors for therapy and screening
04/04/2002WO2001087376A8 Drug/drug delivery systems for the prevention and treatment of vascular disease
04/04/2002WO2001087263A3 Delivery systems for treatment of vascular disease
04/04/2002WO2001085980A3 Enzymatic assays for screening anti-cancer agents
04/04/2002WO2001085910A3 Agents that modulate dna-pk activity and methods of use thereof
04/04/2002WO2001085694A3 Substituted diamide derivatives useful as motilin antagonists
04/04/2002WO2001085142A8 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
04/04/2002WO2001083714A3 Composition and methods for treating photoreceptor degeneration
04/04/2002WO2001081332A3 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
04/04/2002WO2001081308A3 Aminopiperidines for use as glyt-1 inhibitors
04/04/2002WO2001080841A3 Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis
04/04/2002WO2001080830A3 Pharmacotherapeutic process and composition for central nervous system disorders
04/04/2002WO2001077294A3 Hpv-specific short-mers
04/04/2002WO2001074815A3 Phenyl-substituted imidazopyridines
04/04/2002WO2001074810A3 Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists
04/04/2002WO2001074773A3 Phenyl-substituted indoles as histamine h3-receptor antagonists
04/04/2002WO2001073034A3 Beta-like glycoprotein hormone polypeptide and heterodimer
04/04/2002WO2001073033A3 Anti-angiogenic and anti-tumor properties of matin and other laminin domains
04/04/2002WO2001072846A3 Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof
04/04/2002WO2001071022A3 Lpa receptor agonists and antagonists and methods of use
04/04/2002WO2001071017A3 Modified nodavirus rna for gene delivery
04/04/2002WO2001070678A3 Substituted biphenyl derivatives